Clinical Trials Browser

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04853017 2025-09-05

AMPLIFY-201

Phase 1 Completed

25 enrolled 15 charts

GastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Neoplasm, Residual

NCT06993675 2025-08-29

ROTATE

Phase 2 Recruiting

50 enrolled

Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

120 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Clinical Trials

FLAMINGO-01

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

ALPHA3

EMAT

CASSIOPEIA

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

MiRaDoR

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

PREDICT-RD

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

LAL-2025

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Motixafortide for MRD Sensitization in AML

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

CELERITY

FIL_GAZEBO

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

S101MRD

AlloNK1

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

MRD-ATLAS

NeckTAR-IN

ICLL07GAI

HTLP-ONCO

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

GOLD

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Modified Vaccine for High Risk or Low Residual Melanoma Patients

UNITY

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

VERDI

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

AMPLIFY-201

ROTATE

MRD-positive AML Clinical Study